[On early transfer of new cases of pulmonary tuberculosis to outpatient treatment]. / O rannem perevode na ambulatornoe lechenie vpervye vyiavlennykh bol'nykh tuberkulezom legkikh.

Based on 228 clinical cases, the authors propose procedures for complex two-stage (inpatient and outpatient) treatments of new cases of pulmonary tuberculosis by using intermittent intravenous chemotherapy that makes it possible to have a high therapeutic effect in a short space of time, to reduce the duration of hospital treatment substantially, to on the average 2-4 months, and to ensure controlled chemotherapy at the outpatient stage.

[Modalities of complex therapy in different categories of patients with pulmonary tuberculosis]. / Varianty kompleksnoi terapii razlichnykh kategorii bol'nykh tuberkulezom legkikh.

The paper proposes the standards of combined treatment involving intermittent intravenous bactericidal chemotherapy for different groups of patients. It describes treatment regimens at the inpatient stage, defines the scope and time of control examination and correction of a treatment protocol by taking into account the pattern, phase, and dissemination of a process and the duration of the disease.

[Organization of in- and outpatient treatment of new cases of destructive pulmonary tuberculosis]. / Organizatsiia statsionarno-ambulatornogo lecheniia vpervye vyiavlennykh bol'nykh destruktivnym tuberkulezom legkikh.

A system of in- and outpatient treatment of the first detected patients with destructive pulmonary tuberculosis is proposed. The use of various types of intravenous intermittent chemotherapy in patients with focal, infiltrative, and disseminated tuberculosis provides a high efficiency in the inpatient period (the mean time of sputum negativation is 1.6 months, that of destruction closure is 3.1 months) and early (in 2 - 3 months) transfer of these patients to outpatient additional treatment by continuing etiotropic therapy that has turned out to be effective in hospital.

[Possibilities of the use of immobilized proteolytic enzyme immozymase in tuberculosis]. / Vozmozhnosti primeneniia immobilizovannogo proteoliticheskogo fermenta immozimazy vo ftiziatrii.

The paper summarises the experience gained in the use of immozymase in tuberculous patients to advance the disease diagnosis and treatment. Immozymase proved valuable in obtaining sputum enriched with M. tuberculosis in patients who were previously considered noncarriers. M. tuberculosis became detectable in 28.3% of them. Immozymase instillations of the urethra before its massage for stimulation of prostatic secretion led to getting secretion in all the patients (0.35 ml, on the average). Immuzymase inhalations were used in the treatment of purulent bronchitis in patients with destructive pulmonary tuberculosis in conservative and preoperative regimens. Postoperative immozymase inhalations promoted prevention of pleuropulmonary complications. Open treatment of the caverns with immozymase after cavernotomy shortens the treatment duration. Positive results were also reached in the treatment of pleural empyema.

[Quantitative characteristics of immunity in patients with reactivated pulmonary tuberculosis]. / Kolichestvennye kharakteristiki immuniteta u bolnykh s reaktivatsiei tuberkuleza legkikh.

Immune status was assessed in 44 patients with pulmonary re-infection tuberculosis using monoclonal antibodies. Quantitative indices of the immune status (relative amount of T-cells, T-helpers, T-suppressors, natural killers) correlated with tuberculosis activity. It is important to identify immunity-compromised subjects among tuberculous patients to rule out relapses with the help of early immunocorrection.

[The comprehensive diagnosis and therapy of nonspecific bronchitis in patients with newly detected pulmonary tuberculosis]. / Kompleksnaia diagnostika i terapiia nespetsificheskikh bronkhitov u bol'nykh s vpervye vyiavlennym tuberkulezom legkikh.

160 patients with destructive pulmonary tuberculosis of new onset were examined in a tuberculosis hospital. All of them were suspected of being ill with nonspecific bronchial disease after a questionnaire screening. Nonspecific bronchitis was diagnosed in 102 (63.7%) of them. The authors provided the criteria assessing the degree and characteristics of the bronchial tree mucous inflammation by reading endocytopulmonograms. Antituberculosis therapy combined with inhalations (including immozymase) leads to a 13% rise in the efficacy of tuberculosis treatment (cavern closure) and to a 2.5-week reduction in the terms of nonspecific bronchitis cure.

[Clinical aspects and outcome of recurrent pulmonary tuberculosis]. / Klinicheskoe techenie i iskhody retsidiva tuberkulëza lëgkikh.

Recurrent tuberculosis was treated in hospital in 86 patients, 82.7% of whom had destructive disease, while 84.0% disseminated the bacteria. Combined chemotherapy included 4 tuberculostatic drugs: 10% isoniazid (7 mg/kg iv drip), streptomycin (0.5 g intramuscularly), rifadin (0.6 g orally) and tisamid (25-30 mg/kg orally). The drugs were given twice a week under the intermittent regimen in combination with 10% isoniazid (7 mg/kg) and streptomycin (0.5 g) inhalations. During a mean hospital stay of 6.5 months disappearance of destruction and discontinuation of the bacilli dissemination were achieved in 91.1% and 93.9% of patients, respectively, suffering from infiltrative and disseminated tuberculosis.